Meet the Expert

Angila Berni
Angila Berni
Personal Trainer
SFG1 & ACE Personal Trainer
TRX Suspension Trainer
Registered Yoga Instructor with Yoga Alliance
CPR/First Aid/AED Certified

Being healthy and physically fit has always been important to Angila, but it is now her way of life. She hopes to share this love with others to help them become happier and healthier. Her favorite aspect of being a trainer is to see the smiles on her clients’ faces when they achieve their goals.

Angila is a professor of Exercise Science at the University of North Carolina Wilmington, where she obtained her undergraduate degree. She completed her Master of Science in kinesiology, with a concentration in sports conditioning and orthopedic rehabilitation, at A.T. Still University. She has contributed several research projects in her field and presented at the 2014 American College of Sports Medicine conference in Orlando, Florida. Angila is the founder of ATP Fitness, a boutique gym that specializes in personal training and small group fitness.

Her certifications and experience Include SFG 1, SFG II, ACE Personal Trainer, TRX Suspension Trainer, TRX RIP Stick, 200-Hour Registered Yoga Instructor with Yoga Alliance, Track and Field Coach, CrossFit Mobility, Muscle Driver Olympic Lifting, Attitude Nation Level 1 Weightlifting, and CPR/First Aid/Automated External Defibrillator (AED).

Angila Berni is a paid consultant to Acella Pharmaceuticals, LLC.

Important Risk Information

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
  • In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
  • Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
  • The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
  • Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
  • In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
  • Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
  • Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
  • NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.


NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.

NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.